In one paragraphArticle in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Liana SignoriniGraduate Program in Pharmaceutical Sciences, Laboratory of the Research Group on Metabolic Diseases, Federal University of Parana, Curitiba 80210-170, Brazil.
Waldemar VolanskiGraduate Program in Pharmaceutical Sciences, Laboratory of the Research Group on Metabolic Diseases, Federal University of Parana, Curitiba 80210-170, Brazil.
Ademir Luiz do PradoGraduate Program in Pharmaceutical Sciences, Laboratory of the Research Group on Metabolic Diseases, Federal University of Parana, Curitiba 80210-170, Brazil.ORCID 0000-0002-9914-3831 Glaucio ValdameriGraduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, Brazil.ORCID 0000-0003-1882-1512 Mauren Isfer AnghebemGraduate Program in Pharmaceutical Sciences, Laboratory of the Research Group on Metabolic Diseases, Federal University of Parana, Curitiba 80210-170, Brazil.ORCID 0000-0003-3436-9482 Vivian Rotuno MoureGraduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba 80210-170, Brazil.ORCID 0000-0003-0968-8190 Marcel Henrique Marcondes SariGraduate Program in Pharmaceutical Sciences, Laboratory of the Research Group on Metabolic Diseases, Federal University of Parana, Curitiba 80210-170, Brazil.ORCID 0000-0002-9913-9306 Geraldo PichethGraduate Program in Pharmaceutical Sciences, Laboratory of the Research Group on Metabolic Diseases, Federal University of Parana, Curitiba 80210-170, Brazil.
Fabiane Gomes de Moraes RegoGraduate Program in Pharmaceutical Sciences, Laboratory of the Research Group on Metabolic Diseases, Federal University of Parana, Curitiba 80210-170, Brazil.ORCID 0000-0003-1726-8524 Funding
National Council for Scientific and Technological Development 405828/2025-0National Council for Scientific and Technological Development 407034/2023-4
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
artificial intelligencebinomial logistic regressionclusterintermediate hyperglycemiak-meansknowledge discovery databaselipid biomarkersROC curve
Identifiers
PMID41898297
PMCPMC13024570
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390